About this trial
The overall goal of this project is to understand the mechanisms by which gastric bypass surgery improves glucose metabolism.
The central hypothesis guiding this project is that the reconfiguration of intestinal transit with the Roux-en-Y will increase the release of insulinotropic GI hormones, termed incretins that improve insulin secretion and glucose metabolism. The study is divided into three specific aims.
1. To determine the role of incretin hormones on insulin secretion in patients with gastric bypass surgery using intravenous-oral hyperglycemic clamp. 2. To compare incretin effect and glucose tolerance among patient who suffer from hypoglycemia after RYGB and asymptomatic surgical and non-surgical individuals. 3. To quantify the contribution of GLP-1 to incretin effect enhancement following surgery.
Eligibility criteria
Qualifiers
age 18-65
healthy control without diabetes or active organ disease
Individuals with bariatric surgery
recurrent hypoglycemia post gastric bypass
Disqualifiers
pregnancy
significant anemia
diabetes currently unless pre-op for bariatric surgery procedure
GI obstruction
Trial design
Treatments tested in this trial
- exendin-(9-39)
- exendin -(9-39)